- Home
- BCDA vs IDAI Comparison
BCDA vs IDAI Comparison
Compare BCDA & IDAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCDA
- IDAI
- Stock Information
- Founded
- BCDA N/A
- IDAI 2016
- Country
- BCDA United States
- IDAI United States
- Employees
- BCDA 17
- IDAI N/A
- Industry
- BCDA Biotechnology: Pharmaceutical Preparations
- IDAI Computer Software: Prepackaged Software
- Sector
- BCDA Health Care
- IDAI Technology
- Exchange
- BCDA Nasdaq
- IDAI Nasdaq
- Market Cap
- BCDA 13.7M
- IDAI 11.6M
- IPO Year
- BCDA N/A
- IDAI N/A
- Fundamental
- Price
- BCDA $1.32
- IDAI $4.64
- Analyst Decision
- BCDA Strong Buy
- IDAI Strong Buy
- Analyst Count
- BCDA 1
- IDAI 1
- Target Price
- BCDA $25.00
- IDAI $12.00
- AVG Volume (30 Days)
- BCDA 125.5K
- IDAI 219.3K
- Earning Date
- BCDA 11-12-2025
- IDAI 11-07-2025
- Dividend Yield
- BCDA N/A
- IDAI N/A
- EPS Growth
- BCDA N/A
- IDAI N/A
- EPS
- BCDA N/A
- IDAI N/A
- Revenue
- BCDA N/A
- IDAI $3,366,415.00
- Revenue This Year
- BCDA N/A
- IDAI $25.13
- Revenue Next Year
- BCDA N/A
- IDAI $164.45
- P/E Ratio
- BCDA N/A
- IDAI N/A
- Revenue Growth
- BCDA N/A
- IDAI N/A
- 52 Week Low
- BCDA $1.00
- IDAI $1.43
- 52 Week High
- BCDA $3.20
- IDAI $18.75
- Technical
- Relative Strength Index (RSI)
- BCDA 43.26
- IDAI 65.53
- Support Level
- BCDA $1.25
- IDAI $3.52
- Resistance Level
- BCDA $1.45
- IDAI $4.90
- Average True Range (ATR)
- BCDA 0.08
- IDAI 0.43
- MACD
- BCDA 0.00
- IDAI 0.02
- Stochastic Oscillator
- BCDA 27.00
- IDAI 76.24
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About IDAI T Stamp Inc.
T Stamp Inc develops and markets identity authentication software solutions for enterprise partners and peer-to-peer markets. The company is engaged in developing proprietary artificial intelligence-powered solutions; researching and leveraging biometric science, cryptography, and data mining to deliver insightful identity & trust predictions while identifying and defending against fraudulent identity attacks, protecting sensitive user information, and extending the reach of digital services through accessibility. The artificial intelligence-powered solutions segment generates revenue principally from software licenses, professional services, and recurring Software-as-a-Service ("SaaS") revenue.